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1 
METHOD OF IDENTIFYING AND 
TREATING INVASIVE CARCINOMAS 
This invention relates to prostasin and its use in the 
diagnosis and treatment of prostate and breast cancers, and 
claims the priority to U.S. Provisional Application Serial 
No. 60/174,801 filed Jan. 6, 2000 and was supported in part 
by Department of Defense Prostate Cancer Research Grant 
DAMD17-98-l-8590, and in part by grants to principal 
investigator K. X. CHAI from the Florida Hospital Gala 
Endowed Program for Oncologic Research. 
BACKGROUND AND PRIOR ART 
For men in the U.S., prostate cancer is the most com-
monly diagnosed cancer, and the second leading cause of 
cancer-related death (Greenlee R. T., Murray T. Bolden S, 
Wingo Pa. Cancer statistics, 1999. Ca: a Cancer Journal for 
Clinicians 2000;50:7-33). Prostate cancers originate as 
localized lesions; some of these localized lesions will 
progress to become invasive, migratory and metastatic. Our 
current understanding of the mechanisms of the prostate 
cancer invasion process, however, is poor. Our ability to 
predict the acquisition of invasive potentials by a prostate 
cancer is limited. 
The mechanisms leading to the development of a prostate 
cancer are complex. Currently, it is believed to be the result 
of multiple transformation steps from normal prostate glan-
dular cells (Carter H. B. Piantadosi S. Isaacs J. T. Clinical 
evidence for and implications of the multistep development 
of prostate cancer. Journal of Urology. 143(4):742-6, 1990). 
The initial steps result in what are described as prostatic 
interepithelial neoplastic (PIN) lesions (Isaacs J. T. Molecu-
lar markers for prostate cancer metastasis. Developing diag-
nostic methods for predicting the aggressiveness of prostate 
cancer. [Review] [92 refs] American Journal of Pathology. 
150(5):1511-21, 1997). These PIN lesions may then typi-
cally have three different fates based on an assessment of 
their impact to the patient. The PIN lesions can remain as 
such, not producing histologically detectable prostate 
cancer, or further transform into histologically detectable 
prostate cancer. Most of the histologically detectable pros-
tate cancers will be asymptomatic in the patient and remain 
non-manifest clinically as many are discovered post-mortem 
(Carter H Coffey D. Prostate Cancer: the magnitude of the 
problem in the United States. In a Multidisciplinary Analysis 
of Controversies in the Management of Prostate Cancer. 
(Eds. Coffey D. Resnick M. Door R. et al.), ppl-9, Plenum 
Press, 1988; Carter H B Piantadosi S. Issacs J. T. Clinical 
evidence for implications of the multistep development of 
prostate cancer. Journal of Urology. 143(4):742-6,1990; 
Scardino P T. Weaver R. Hudson M A Early detection of 
prostate cancer. [Review] [102 refs] Human Pathology. 
23(3):211-22, 1999). Prostate cancers are diagnosed clini-
cally by an estimate of size and location using the TNM 
staging system (Denis L J. Staging and prognosis of prostate 
cancer. European Urology. 24 Suppl 2:13-8, 1993), and by 
pathological staging based on an examination of the histol-
ogy of the removed prostate via either biopsy or prostatec-
tomy using a system by D. F. Gleason, (Gleason D F. 
Classification of prostatic carcinomas. Cancer Chemo-
therapy Reports-Part 1. 50(3):125-8, 1966). About 50% of 
prostate cancer cases receiving treatment are diagnosed 
clinically as advanced, or, non-organ-confined (Scardino P 
T. Weaver R. Hudson M A Early detection of prostate 
cancer. [Review] [102 refs] Human Pathology. 23(3): 
211-22, 1992), for which no effective treatment exists 
(Yagoda A Petrylak D. Cytotoxic chemotherapy for 
2 
advanced hormone-resistant prostate cancer. [Review] [ 63 
refs] Cancer. 71(3 Suppl): 1098-109, 1993 and Petrylak, 
1993). Of the remaining 50% cases, 1/3 (-50,000) are 
diagnosed as organ-confined but micrometastasis may be 
5 present. The final group of patients (-100,000) have truly 
organ-confined prostate cancer and can be cured by radical 
prostatectomy (Sgrignoli AR Walsh P C. Steinberg G D. 
Steiner M S. Epstein J I. Prognostic factors in men with 
stage D 1 prostate cancer: identification of patients less 
10 likely to have prolonged survival after radical prostatectomy 
[see comments]. Journal of Urology. 152(4):1077-81, 1994; 
Zincke H. Oesterling J E. Blute ML. Bergstralh E J. Myers 
R P. Barrett D M. long term (15 years) results after radical 
prostatectomy for clinically localized (stageT2c or lower) 
15 prostate cancer [see comments]. Journal of Urology. 152(5 
Pt 2): 1850-7, 1994) or left untreated (watchful waiting) 
without the risk of life-threatening or life-altering. For the 
patients with non-organ-confined prostate cancers 
(discovered via either biopsy or surgery), undergoing sys-
20 temic treatment early is essential to the management of their 
cancer (Yagoda A Petrylak D. Cytotixic chemotherapy for 
advanced hormone-resistant prostate cancer [Review] [ 63 
refs] Cancer. 71(3 Suppl): 1098-109, 1993). Consequently, 
it will be ideal, both medically and economically, if one 
25 could precisely predict upon early pathological examination 
of the tumor, which group of patients will have truly 
organ-confined disease versus which group will have inva-
sive prostate cancer. 
Clinical staging of prostate cancer generally depends on 
30 the results of three tests that are performed in the following 
order: a PSA (prostate-specific antigen) blood test as a 
screening method; DRE (digital rectal examination) for an 
initial indication of palpable disease; and, a biopsy to obtain 
samples for histological examination. Prostate cancers, 
35 removed either via biopsy or surgery, are graded histologi-
cally by the system of Gleason. (Gleason D F. Classification 
of prostatic carcinomas. Cancer Chemotherapy Reports-
Partl. 50(3):125-8, 1966), which is an evaluation of how 
aggressive and how poorly-differentiated the prostate can-
40 cers are. The aggressiveness of prostate tumors: of low 
Gleason scores ( <5) is limited; of high Gleason scores 
(8-10) are highly aggressive; but, for the intermediate 
Gleason-score (5-7) prostate cancers (76% of prostate 
tumors), the accuracy of predicting their aggressiveness is 
45 poor (Gleason D F. Mellinger GT. Prediction of prognosis 
for prostatic adenocarcinoma by combined histological 
grading and clinical staging. Journal of Urology. 111 
(1):58-64, 1974). Thus, the ability to accurately determine 
the aggressiveness of these intermediate Gleason-score 
50 prostate tumors has remained as a practical challenge to, and 
a primary goal for, prostate cancer research (Isaacs J T. 
Molecular markers for prostate cancer metastasis. Develop-
ing diagnostic methods for predicting the aggressiveness of 
prostate cancer. [Review] [92 refs] American Journal of 
55 Pathology. 150(5): 1511-21, 1997). Especially with regard to 
the number of patients (150,000) facing a decision of 
whether to undergo systemic treatment, the most urgent 
demand in prostate cancer care is the development of 
methods to enhance our ability to accurately predict the 
60 aggressiveness of the tumors with Gleason scores of 5-7. 
It is now commonly believed that cancers occur via 
multiple transformation steps by accumulating mutations in 
three classes of genes: proto-oncogenes (Park M. Onco-
genes. In The Genetic Basis of Human Cancer (Eds. Vogel-
65 stein Band Kinzler KW), pp205-28, McGraw-Hill Health 
Professions Divisions, 1998); tumor-suppressor genes 
(Knuutila S. Aalto Y. Bjorkqvist AM. EL-Rifai W. Hemmer 
US 6,569,684 B2 
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S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy M 
L. Lushnikova T. Manni 0. Pere H. Tapper J. Tarkkanen M. 
Varis A Wasenius V M. Wolf M. Zhu Y. DNA copy number 
losses in human neoplasms. [Review] [197 refs] American 
Journal of Pathology. 155(3):683-94, 1999); and, DNA 5 
repair genes (Knuutila S. Aslto Y. Bjorkqvit AM. EL-Rifai 
4 
prognosis in patients with prostate cancer. Cancer Research. 
54(14):3929-33, 1994); ~ic integrin (Fornaro M. Tallini G. 
Bofetiado CJ. Bosari S. Languino LR. Down-regulation of 
~lC integrin, an inhibitor of cell proliferation, in prostate 
carcinoma. American Journal of Pathology. 149(3):765-73, 
1996 Fornaro M. Manzotti M. Tallini G. Slear A E. Bosari 
S. Ruoslahti E. Languino LR. ~lC integrin in epithelial cells 
correlates with a nonproliferative phenotype: forced expres-
sion of ~lC inhibits prostate epithelial cell proliferation. 
10 American Journal of Pathology. 153(4):1079-87, 1998; p27 
(kipl) (Tsihlias J. Kapusta LR. DeBoer G. Morava-Protzner 
I. Zbieranowski I. Bhattacharya N. Catzavelos G C. Klotz L 
H. Slingerland JM. Loss of cyclin-dependent kinase inhibi-
tor p27Kipl is a novel prognostic factor in localized human 
W. Hemmer S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. 
Larramedy ML. Lushnikova T. Manni 0. Pere H. Tapper J. 
Tarkkanen M. VarisA. Wasenius V M. Wolf M. Zhu Y. DNA 
copy number losses in human neoplasms. [Review] [197 
refs] American Journal of Pathology. 155(3):683-94, 1999). 
The histological prostate cancers for which the prediction of 
clinical aggressiveness is difficult (those with the interme-
diate Gleason scores 5-7) probably have not gone through 
the necessary "multi-step" transformation to acquire the 
potentials to behave aggressively (as would the high-grade 
cancers). This notion was supported by studies comparing 
the course of prostate cancer development among men in 
Japan and in the U.S., and Japanese men who migrated to the 
U.S. (Carter H B. Piantadosi S. Isaacs J T. Clinical evidence 20 
for and implications of the multistep development of pros-
tate cancer. Journal of Urology, 1990; Haenszel W. Kurihara 
15 prostate adenocarcinoma. Cancer Research. 58(3):542-8, 
1998); and CD44 (Lou W. Krill D. Dhir R. Becich M J. Dong 
J T. Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C. 
Methylation of the CD44 metastasis suppressor gene in 
M. Studies of Japanese Migrants. I. Mortality form cancer 
and other diseases among Japanese in the United States. 
Journal of the National Cancer Institute.40(1):43-68, 1968; 25 
Akazaki K. Stemmerman G N. Comparartive study of latent 
carcinoma of the prostate among Japanese in Japan and 
Hawaii. Journal of the National Cancer Institute. 50(5): 
1137-44, 1973; Dunn J E. Cancer epidemiology in popula-
tions of the United States-with emphasis on Hawaii and 30 
California-and Japan. Cancer Research. 35(11 Pt.2): 
3240-5, 1975). The findings were that first- and second-
generation Japanese men who migrated to the U.S. have a 
higher prostate cancer incident rate than native Japanese 
men. The emigrant Japanese men's prostate cancer incident 35 
rate is similar to that of men in the U.S. Investigating the 
changes of expression in these three classes of cancer-
relevant genes during the course of prostate cancer devel-
opment will lead to a better understanding of the processes 
human prostate cancer. Cancer Research. 59(10):2329-31, 
1999). By using the method of immunohistochemistry, these 
genes were found to be down-regulated in prostate cancer. 
KAI's down regulation is a potential predictor of metastasis 
(Dong, et al., 1996: Ueda et al., 1996). While E-cadherin's 
down regulation is strongly correlated to higher Gleason 
grades. Functional studies of these genes have given clues to 
their role in prostate cancer or normal prostate biology. 
(Debruyne F M. Isaacs W B. Expression of the cellular 
adhesion molecule E-cadherin is reduced or absent in high-
grade prostate cancer. Cancer Research. 52(18):5104--9, 
1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE. 
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A 
Decreased E-cadherin expression is associated with poor 
prognosis in patients with prostate cancer. Cancer Research. 
54(14):3929-33, 1994; metastasis suppressor gene during 
the progression of human prostatic cancer infrequently 
involves gene mutation or allelic loss. Cancer Research. 
56(19):4387-90; 1996 Ueda T. Ichikawa T. Tamaru J. 
Mikata A Akakura K. Akimoto S. Imai T. Yoshie 0. 
Shiraishi T. Yatani R. Ito H. Shimazaki J. Expression of the 
KAil protein in benign prostatic hyperplasia and prostate 
cancer. American Journal of Pathology. 149(5):1435-40, 
1996) while E-cadherin's down-regulation is strongly cor-
related to higher Gleason grades (Umbas R. Schalken J A 
Aalders T W. Carter B S. Karthaus H F. Schaafsma H E. 
by which prostate cancers acquire their aggressive paten- 40 
tials. The discovery of molecules whose changes can be 
correlated to the staging of prostate cancer will provide new 
tools to improve our ability to better predict the aggressive 
behaviors of prostate cancer. This approach is now com-
monly referred to as "molecular staging". 
Down-regulated genes such as tumor suppressors, inva-
sion suppressors or metastasis suppressors may be used as 
prostate cancer markers. Examples of these genes that can 
potentially serve as prostate cancer markers for "molecular 
staging" are: KAil (Dong J T. Suzuki H. Pin S S. Bova G 50 
S., Schalken J A, Issacs W B, Barrett J C. Issace I T. 
Down-regulation of the KAil metastasis suppressor gene 
during the progression of human prostatic cancer infre-
quently involves gene mutation or allelic loss. Cancer 
Research. 56(19): 4387-90, 1996); (Ueda T, Ichikawa T., 55 
Tamaru j, Mikata A, Akakura K, Akimoto S, Imai T. Yoshie 
45 Debruyne F M. Isaacs W B. Expression of the cellular 
adhesion molecule E-cadherin is reduced or absent in high-
grade prostate cancer. Cancer Research. 52(18):5104--9, 
1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE. 
0. Shiraishi T. Yatani R. Ito H. Shimazaki J., Expression fof 
the KAll protein in benign prostatic hyperplasia and pros-
tate cancer. American Journal of Pathology 149(5): 
1435-40, 1996); E-cadherin (Umbas R. Isaacs W B Brin- 60 
guier PP. Schaafsma H E. Karthaus H F. Oosterhof G 0. 
Debruyne FM. Schalken J A Decreased E-Cadherin expres-
sion is associated with poor prognosis is patients with 
prostate cancer. Cancer Research. 52(18):5104-9, 1992, 
Umbas R. Isaacs W B. Bringuier P P. Schaafsma H E. 65 
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A 
Decreased E-cadherin expression is associated with poor 
Karthaus HF. Oosterhof G 0. Debruyne FM. Schalken J A 
Decreased E-cadherin expression is associated with poor 
prognosis in patients with prostate cancer. Cancer Research. 
54(14):3929-33, 1994) Functional studies of these genes 
have given clues to their role in prostate cancer or normal 
prostate biology. Human KAI suppress metastasis of rat 
prostate cancer cells upon gene transfer (Dong JT. Lamb P 
W. Rinker-Schaeffer C W. Vukanovic J. Ichikawa T. Isaacs 
J T. Barrett J C. KAil, a metastasis suppressor gene for 
prostate cancer on human chromosome llpll.2 [see 
comments]. Science. 268(5212):884-6, 1995). ~ic and p27 
(kip1 ) are involved in signaling pathway that inhibits cell 
proliferation (Fornaro M. Tallini G. Zheng D Q. Flanagan W 
M. Manzotti M. Languino LR. p27(kipl) acts as a down-
stream effector of and is coexpressed with the betalC 
integrin in prostatic adenocarcinoma. Journal of Clinical 
Investigation. 103(3):321-9, 1999). E-cadherin expression 
is progressively lost during the transformation of rat prostate 
cancer from non-invasive to invasive (Bussemakers M J. 
US 6,569,684 B2 
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van Moorselaar R J. Giroldi LA Ichikawa T. Isaacs J T. 
Takeichi M. Debruyne F M. Schalken J A Decreased 
expression of E-cadherin in the progression of rat prostatic 
cancer. Cancer Research. 52(10):2916-22, 1992), and it has 
also been shown to be an invasion suppressor (Lou W. Krill 
D. Dhir R. Becich M J. Dong J T. Frierson HF Jr. Isaacs W 
B. Isaacs J T. Gao AC. Methylation of the CD44 metastasis 
suppressor gene in human prostate cancer. Cancer Research. 
59(10):2329-31, 1999). CD44 loss of expression is associ-
ated with high metastatic ability and transfection of CD44 
suppresses metastasis without affecting tumorigenecity of 
rat prostate cancer cells (Gao AC. Lou W. Dong J T. Isaacs 
J T. CD44 is a metastasis suppressor gene for prostatic 
cancer located on human chromosome llp13. Cancer 
Research. 57(5):846-9, 1997). CD44 down-regulation is a 
prognostic marker for prostate cancer (Noordzij M A van 
Steenbrugge G J. Verkaik NS. Schroder F H. van der Kwast 
T H. The prognostic value of CD44 isoforms in prostate 
cancer patients treated by radical prostatectomy. Clinical 
Cancer Research. 3(5):805-15, 1997). 
Human prostate cancer histology is heterogeneous, or 
"multi-focal" in nature (Isaacs J T. Bova G S. Prostate 
Cancer. In The Genetic Basis of Human Cancer (Eds. 
Vogelstein B and Kinzler K W), pp653-60, McGraw-Hill 
Health Professions Division, 1998 and Bova, 1998), with an 
average of five lesions in a patient (Bastacky S I. Wojno K 
J. Walsh P C. Carmichael M J. Epstein J I. Pathological 
features of hereditary prostate cancer. Journal of Urology. 
153(3 Pt 2):987-92, 1995). Between the tumor regions of a 
prostate and within a single tumor region, the genetic causes 
to the cancer are heterogeneous and independent as well 
(Sakr WA Macoska J A Benson P. Grignon D J. Wolman 
S R. Pontes J E. Crissman J D. Allelic loss in locally 
metastatic, multisampled prostate cancer. Cancer Research. 
54(12):3273-7, 1994; Qian J. Bostwick D G. Takahashi S. 
Borell T J. Herath J F. Lieber M M. Jenkins R B. Chromo-
somal anomalies in prostatic intraepithelial neoplasia and 
carcinoma detected by fluorescence in situ hybridization. 
Cancer Research. 55(22):5408-14, 1995; Mirchandani D. 
Zheng J. Miller G J. Ghosh AK. Shibata D K. Cote R J. 
Roy-Burman P. Heterogeneity in intra tumor distribution of 
p53 mutations in human prostate cancer. American Journal 
of Pathology. 147(1):92-101, 1995). In the end, the best 
predictor of prostate cancer's potential to gain invasiveness 
may be a consideration of a number of genes whose expres-
sion levels change along the course of cancer development, 
as demonstrated in principle by Greene et al. (Greene G F. 
Kitadai Y. Pettaway CA von Eschenbach AC. Buucana C 
D. Fidler I J. Correlation of metastasis-related gene expres-
sion with metastatic potential in human prostate carcinoma 
cells implanted in nude mice using an in situ messenger 
RNA hybridization technique. American Journal of Pathol-
ogy. 150(5):1571-82, 1997). Hence, expanding the reper-
tory of such genes, including both the onco-genes and the 
suppressor genes, will enhance the accuracy and depend-
ability of this approach. 
As for the treatment options of prostate cancer, patients 
with truly organ-confined prostate cancer can be cured by 
radical prostatectomy. Patients with non-organ-confined 
prostate cancers, however, have very low survival rates and 
the current treatments are largely ineffective (Yagoda A 
Petrylak D. Cytotoxic chemotherapy for advanced hormone-
resistant prostate cancer. [Review] [63 refs] Cancer. 71(3 
Suppl): 1098-109, 1993). 
Breast cancer is the most diagnosed cancer in women and 
the second leading cancer related cause of death in women 
(Greenlee R T, Murray T, Bolden S, Wingo PA Cancer 
6 
statistics, 1999. Ca: a Cancer Journal for Clinicians 
2000;50:7-33). Breast ductal carcinoma in situ (hereinafter 
indicated as DCIS) incidence has increased dramatically 
since 1983 as a result of implementing screening programs 
5 (Ernster V L. Barclay J. Increases in ductal carcinoma in situ 
(DCIS) of the breast in relation to mammography: a 
dilemma. [Review] [34 refs] Journal of the National Cancer 
Institute. Monographs. (22): 151-6, 1997). DCIS is 
described as a malignant growth of epithelial cells within the 
10 ducts and lobules of the breast, and is believed to be the 
precursor of all invasive breast carcinoma. DCIS itself is 
non-life-threatening; however, current treatment options for 
DCIS include masectomy, lumpectomy, radiotherapy or 
tamoxifen (Ernster V L. Barclay J. Increases in ductal 
15 carcinoma in situ (DCIS) of the breast in relation to mam-
mography: a dilemma. [Review] [34 refs] Journal of the 
National Cancer Institute. Monographs. (22): 151-6, 1997; 
Hwang ES. Esserman LJ. Management of ductal carcinoma 
in situ. [Review] [91 refs] Surgical Clinics of North 
20 America. 79(5):1007-30, viii, 1999). These treatment 
options for DCIS are at best controversial due primarily to 
a lack of precision in diagnosis and prognosis of whether the 
detected DCIS will progress to invasive breast cancer and 
whether recurrence is likely after treatment, usually with a 
25 high percentage being invasive breast cancer (Zaugg K. 
Bodis S. Is there a role for molecular prognostic factors in 
the clinical management of ductal carcinoma in situ (DCIS) 
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
55(2):95-9, 2000). At present, histological grading (nuclear 
30 grading and whether come do-type necrosis is present) and 
the size of the DCIS are used to provide assessments of risk 
of DCIS to progress into invasive breast cancer (Zaugg K. 
Bodis S. Is there a role for molecular prognostic factors in 
the clinical management of ductal carcinoma in situ (DCIS) 
35 of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
55(2):95-9, 2000; Shaker B S. Sloane J P. DCIS grading 
schemes and clinical implications. [Review] [ 40 refs] His-
topathology. 35(5):393-400, 19; van de Vijver M J. Ductal 
carcinoma in situ of the breast: histological classification 
40 and genetic alterations. [Review] [ 69 refs] Recent Results in 
Cancer Research. 152:123-34, 1998). These parameters are 
far from being adequate for making the most accurate choice 
of treatment, resulting in a choice either overly excessive or 
conservative, in either case, the patient will suffer unneces-
45 sarily. Molecular markers can help improve our ability to 
better diagnose DCIS and stratify treatment options, espe-
cially the molecular markers that, themselves, play a role in 
the progression of DCIS to invasive breast cancer (Zaugg K. 
Bodis S. Is there a role for molecular prognostic factors in 
50 the clinical management of ductal carcinoma in situ (DCIS) 
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology. 
55(2):95-9, 2000; Silverstein M J. Masetti R. Hypothesis 
and practice: are there several types of treatment for ductal 
carcinoma in situ of the breast?. [Review] [ 53 refs] Recent 
55 Results in Cancer Research. 152:105-22, 1998). The tum-
origenesis process is a multi-step transformation in which 
molecular events escalate to the final stage of invasive 
phenotype (Silverstein M J. Masetti R. Hypothesis and 
practice: are there several types of treatment for ductal 
60 carcinoma in situ of the breast?. [Review] [ 53 refs] Recent 
Results in Cancer Research. 152:105-22, 1998). The con-
ventional paradigm of protease involvement in the devel-
opment and progression of cancer has been the assignment 
of a usually negative role to the proteases, such as promoting 
65 tumor invasion (Mignatti P. Rifkin D B. Biology and bio-
chemistry of proteinases in tumor invasion. [Review] [306 
refs] Physiological Reviews. 73(1):161-95, 1993). In turn, 
US 6,569,684 B2 
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the conventional paradigm of protease inhibitors in relation 
to cancer is usually regard of a beneficial effect for the 
presence of these molecules (Kennedy AR. Chemopreven-
tive agents: protease inhibitors. Pharmacol Therapeut 
78:167-209, 1998). Recently, however, the picture of a new 5 
paradigm is beginning to emerge for several serine proteases 
in breast, prostate, and testicular cancers. A "normal epithe-
lial cell specific-1" (NESl) serine protease was found to be 
down-regulated in breast and prostate cancers, and it func-
tions as a tumor suppressor (Goyal J, Smith KM, Cowan J 10 
M, Wazer D E, Lee SW, Band V. The role for NESl serine 
protease as a novel tumor suppressor. Cancer Res 
58:4782-4786, 1998). A prostate-specific serine protease, 
prostase (Nelson P S. Gan L. Ferguson C. Moss P. Gelinas 
R. Hood L. Wang K. Molecular cloning and characterization 15 
of prostase, an androgen-regulated serine protease with 
prostate-restricted expression. Proceedings of the National 
Academy of Sciences of the United States of America. 
96(6):3114-9, 1999), was shown to be expressed in normal 
prostate but not in prostate cancer cell lines DU-145 and 20 
PC-3. The expression of a testis-specific serine protease, 
testisin, was shown to be lost in testicular cancer through 
either a loss of gene (Hooper JD. Nicol D L. Dickinson J L. 
Eyre HJ. ScarmanAL. Normyle J F. Stuttgen MA Douglas 
M L. Loveland KA Sutherland G R. Antalis T M. Testisin, 25 
a new human serine proteinase expressed by premeiotic 
testicular germ cells and lost in testicular germ cell tumors. 
Cancer Research. 59(13):3199-205, 1999) or methylation in 
the promoter (Boucaut K, Douglas M, Clements J, Antalis T. 
The serine proteinase testisin may act as a tumor and/or 30 
growth suppressor in the testis and may be regulated by 
DNA methylation. Cancer Genetics and Tumor Suppressor 
Genes, Cold Spring Harbor Laboratory, 2000). Further, 
transfection of human testicular cancer cells with a testisin 
cDNAreduced the tumor growth of xenografts of these cells 35 
in nude mice, suggesting a tumor suppressor function for 
testisin (Boucaut K, Douglas M, Clements J, Antalis T. The 
serine proteinase testisin may act as a tumor and/or growth 
suppressor in the testis and may be regulated by DNA 
methylation. Cancer Genetics and Tumor Suppressor Genes, 40 
Cold Spring Harbor Laboratory, 2000). The testisin serine 
protease is potentially membrane-bound as suggested by its 
structure and confirmed by immunohistochemistry gene 
(Hooper JD. Nicol D L. Dickinson J L. Eyre HJ. Scarman 
AL. Normy le J F. Stuttgen MA Douglas ML. Loveland K 45 
A Sutherland G R. Antalis T M. Testisin, a new human 
serine proteinase expressed by premeiotic testicular germ 
cells and lost in testicular germ cell tumors. Cancer 
Research. 59(13):3199-205, 1999.) Prostasin serine pro-
tease is an acidic protein (pl 4.5-4.8) of approximately 40 50 
kDa in molecular mass (Yu J X. Chao L. Chao J. Prostasin 
is a novel human serine proteinase from seminal fluid. 
Purification, tissue distribution, and localization in prostate 
gland. Journal of Biological Chemistry. 269(29):18843-8, 
1994). It is predominantly made in the prostate gland (-140 55 
ng/mg protein), with lesser amounts (2-6 ng/mg protein) 
also found in the bronchi, colon, kidney, liver, lung, 
pancreas, and the salivary glands (Yu J X. Chao L. Chao J. 
Prostasin is a novel human serine proteinase from seminal 
fluid. Purification, tissue distribution, and localization in 60 
prostate gland. Journal of Biological Chemistry. 269(29): 
18843-8, 1994). Prostasin is secreted in the prostatic fluid, 
and can be detected in the semen (-9 µg/ml). Prostasin 
expression is localized to the epithelial cells of human 
prostate gland by in situ hybridization histochemistry using 65 
an antibody or an anti-sense RNA probe (Yu J X. Chao L. 
Chao J. Prostasin is a novel human serine proteinase from 
8 
seminal fluid. Purification, tissue distribution, and localiza-
tion in prostate gland. Journal of Biological Chemistry. 
269(29): 18843-8, 1994; (Yu J X. Chao L. Chao J. Molecu-
lar cloning, tissue-specific expression, and cellular localiza-
tion of human prostasin mRNA. Journal of Biological 
Chemistry. 270(22): 13483-9, 1995). Molecular cloning of 
a full-length human prostasin cDNA revealed that its pre-
dicted amino acid residue sequence contains a carboxyl-
terminal hydrophobic region that can potentially anchor the 
protein on the membrane (Yu J X Chao L. Chao J. Molecular 
cloning, tissue-specific expression, and cellular localization 
of human prostasin mRNA. Journal of Biological Chemistry. 
270(22):13483-9, 1995). At the amino acid level, prostasin 
is similar to plasma kallikrein, coagulation factor XI, hepsin, 
plasminogen, acrosin, prostase, and, in particular, testisin 
(sharing 44% sequence identity) [Nelson PS. Gan L. Fer-
guson C. Moss P. Gelinas R. Hood L. Wang K. Molecular 
cloning and characterization of prostase, an androgen-
regulated serine protease with prostate-restricted expression. 
Proceedings of the National Academy of Sciences of the 
United States of America. 96(6):3114-9, 1999; Hooper JD. 
Nicol D L. Dickinson J L. Eyre HJ. Scarman AL. Normy le 
J F. Stuttgen MA Douglas M L. Loveland KA Sutherland 
G R. Antalis T M. Testisin, a new human serine proteinase 
expressed by premeiotic testicular germ cells and lost in 
testicular germ cell tumors. Cancer Research. 59(13): 
3199-205, 1999; Yu J X. Chao L. Chao J. Molecular 
cloning, tissue-specific expression, and cellular localization 
of human prostasin mRNA. Journal of Biological Chemistry. 
270(22):13483-9, 1995). A membrane-bound Xenopus kid-
ney epithelial cell sodium channel-activating protease (CAP 
1) was shown to be highly homologous to human prostasin 
as well (sharing 53% sequence identity at the amino acid 
level) (Vallet V. Chraibi A Gaeggeler H P. Horisberger J D. 
Rossier B C. An epithelial serine protease activates the 
amiloride-sensitive sodium channel. Nature. 389(6651): 
607-10, 1997). Prostasin is encoded by a single-copied 
gene, which is located on human chromosome 16pll.2 (Yu 
J X. Chao L. Ward D C. Chao J. Structure and chromosomal 
localization of the human prostasin (PRSS8) gene. Genom-
ics. 32(3):334-40, 1996). The secreted prostasin cleaves 
synthetic substrates in vitro preferentially at the carboxyl-
terminal side of Arg residue, and is thus considered a 
trypsin-like serine protease (Yu J X. Chao L. Chao J. 
Prostasin is a novel human serine proteinase from seminal 
fluid. Purification, tissue distribution, and localization in 
prostate gland. Journal of Biological Chemistry. 269(29): 
18843-8, 1994). The physiological function of prostasin, 
however, has remained unknown. By comparing gene 
expression of normal tissues, pre-invasive cancer, and inva-
sive cancer, it would be highly advantageous to discover 
molecular markers that display a differential expression 
pattern between the pre-invasive and the invasive pheno-
types and use these markers for a more precise diagnosis and 
prognosis of prostate and/or breast cancers. With the 
enhanced precision in diagnosis and prognosis, treatment 
options for patients with DCIS could then be stratified. 
Those with low risks of developing invasive breast cancer 
will have a higher confidence in choosing breast-conserving 
options, while those at high risks will ponder more aggres-
sive options with the necessary follow-up treatments. 
Similarly, those males with low risks of developing invasive 
prostate cancer will have a higher confidence in choosing 
prostate-conserving options, while those at high risks will 
ponder more aggressive options with the necessary follow-
up treatments 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to reduce 
deficiencies in the prior art with specific regard to differen-
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tial diagnosis of invasive prostate and breast cancers and to 
treatment of invasive and metastatic prostate and breast 
cancers. 
10 
FIG. 2 is a diagrammatic representation of the analysis of 
prostasin indicative of the absence or existence, or of the 
invasiveness of human mammary carcinoma. 
The second objective of the present invention is to pro-
vide a new marker for prostate and breast cancer. 
The third objective of the invention is to provide as a drug 
to patients with carcinoma of the prostate via delivery of a 
functional prostasin gene. 
FIG. 3 shows human prostasin expression in prostate 
5 epithelial cells. 
The fourth objective of the invention is to provide as a 
drug to patents with carcinoma of the prostate via delivery 10 
of a functional prostasin cDNA. 
The fifth objective of the invention is to provide as a drug 
to patents with carcinoma of the breast via delivery of a 
functional prostasin gene. 
The sixth objective of the invention is to provide as a drug 15 
to patents with carcinoma of the breast via delivery of a 
functional prostasin cDNA. 
FIG. 4A shows immunohistochemical detection of pros-
tasin protein in benign human prostate tissues. 
FIG. 4B is an enlarged view of the boxed region of FIG. 
4A. 
FIG. 4C shows immunohistochemistry of benign human 
prostate tissues with prostasin antibody omitted in the 
procedures, no epithelial cells displayed any staining. 
FIG. 4D is an enlarged view of the boxed region of FIG. 
4C. 
FIG. 4E shows immunohistochemistry of human prostate 
tumor with prostasin antibody omitted in the procedures, no 
epithelial cells displayed any staining. This invention identifies prostasin serine protease as a 
potential marker, and as a tumor invasion suppressor for 
prostate and breast cancers and thus provides methods (a), 
(b), and (c) of determining invasiveness levels of human 
carcmomas: 
FIG. 4F shows immunohistochemical detection of pros-
20 tasin protein in benign human prostate tissue surrounded by 
prostate carcinomas. 
FIG. 4G shows immunohistochemical detection of pros-
tasin protein in Gleason grade 2 prostate tumor. 
FIG. 4H is an enlarged view of the boxed region of FIG. 
4G. 
FIG. 4I shows immunohistochemical detection of prosta-
sin protein in Gleason grade 3 prostate tumor. 
(a) using prostasin protein levels, comprising the steps of: 
sampling a human carcinoma tissue; determining pros-
tasin protein levels in the human carcinoma tissue; 25 
preferably by applying an immunological reagent-
antibody to said tissue wherein the reagent-antibody 
becomes bound to prostasin protein in said tissue, and 
determining invasiveness of the human carcinoma tis-
sue based on the prostasin protein levels:. or 
FIG. 41 is an enlarged view of the boxed region of FIG. 
30 41. 
(b) using prostasin mRNA levels, comprising the steps of: 
sampling a human carcinoma tissue; determining pros-
tasin mRNA levels in the human carcinoma tissue 
preferably by applying prostasin-specific anti-sense 
RNA probes in an in situ hybridization to determine the 35 
prostasin mRNA levels in the separated human carci-
noma tissue the determination of the prostasin mRNA 
levels in the separated human carcinoma sample tissue; 
to make possible and determining invasiveness of the 
human carcinoma tissue based on the prostasin mRNA 40 
levels; or 
FIG. 4K shows immunohistochemical detection of pros-
tasin protein in Gleason grade 4 prostate tumor. 
FIG. 4L is an enlarged view of the boxed region of FIG. 
4K. 
FIG. 5 shows human prostasin expression in human breast 
cancer cell lines. 
FIG. 6 shows promoter hypermethylation of the human 
prostasin gene in human prostate and breast cancer cell lines. 
FIG. 7 shows prostasin protein expression and in vitro 
invasive properties of the DU-145 and the PC-3 transfec-
tants. 
FIG. 8 shows prostasin protein expression and in vitro 
invasive properties of the MDA-MB-231 and the MDA-
45 MB-435s transfectants. 
(c) (c) using prostasin gene promoter DNA methylation 
levels, comprising the steps of: sampling a human 
carcinoma tissue; determining prostasin gene promoter 
DNA methylation levels in the human carcinoma 
tissue, preferably by applying prostasin-promoter-
specific oligonucleotide primers in a PCR to determine 
the prostasin gene promoter DNAmethylation levels in 
the sampled human carcinoma tissue and determining 
invasiveness of the human carcinoma tissue based on 50 
the prostasin gene promoter DNA methylation levels, 
as well as a method of treating invasive human carcinomas 
comprising the steps of: incorporating human prostasin 
nucleic acid into a selected gene delivery vector nucleic acid 
to form a recombinant nucleic acid; preferably wherein the 55 
nucleic acid includes a gene or cDNA delivering the recom-
binant nucleic acid into a human carcinoma; and reducing 
invasiveness of the human carcinoma. 
Further objects and advantages of this invention will be 
apparent from the following detailed description of a pres- 60 
ently preferred embodiment, which is illustrated schemati-
cally in the accompanying drawings. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
Before explaining the disclosed embodiment of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
Using RT-PCR and western blot analyses, prostasin pro-
tein and mRNA expression were found in normal human 
prostate epithelial cells and the human prostate cancer cell 
line LNCaP, but discovered not present in the highly inva-
sive human prostate cancer cell lines DU-145 and PC-3. 
Immunohistochemistry studies of human prostate cancer 
specimens revealed a down-regulation of prostasin in high-
grade tumors. 
BRIEF DESCRIPTION OF THE FIGURE 
FIG. 1 is a diagrammatic representation of the analysis of 
prostasin indicative of the absence or existence, or of the 
invasiveness of human prostate carcinoma. 
Using RT-PCR and western blot analyses, prostasin pro-
65 tein and mRNA expression were found in a non-invasive 
human breast cancer cell line, MCF-7, while invasive human 
breast cancer cell lines MDA-MB-231 and MDA-MB-435s 
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were also discovered not to express either the prostasin 
protein or the mRNA. A non-invasive human breast cancer 
cell line, MDA-MB-453, was shown to express prostasin 
mRNA but not prostasin protein. Examination of the pros-
tasin gene promoter in the human prostate and breast cancer 5 
cell lines by Southern blot analysis revealed heterogeneous 
methylation of the promoter in DU-145, PC-3 and MDA-
MB-453 cells, and homogeneous methylation of the pro-
moter in MDA-MB-231 and MDA-MB-435s cells. The 
prostasin gene promoter in normal human prostate epithelial 10 
cells, the LNCaP and the prostasin gene promoter in the 
human prostate and breast cancer cell lines by Southern blot 
analysis revealed heterogeneous methylation of the pro-
moter in DU-145, PC-3 and MDA-MB-453 cells, and homo-
geneous methylation of the promoter in MDA-MB-231 and 15 
MDA-MB-435s cells. The prostasin gene promoter in nor-
mal human prostate epithelial cells, the LNCaP and the 
MCF-7 cells was shown to be unmethylated. Transfection of 
DU-145 and PC-3 cells with a full-length human prostasin 
cDNArestored prostasin expression and reduced the in vitro 20 
invasiveness by 68% and 42%, respectively. Transfection of 
MDA-MB-231 and MDA-MB-435s cells with a full-length 
human prostasin cDNA restored prostasin expression and 
reduced the in vitro invasiveness by 50% for either cell line. 
Cell proliferation was unaffected by re-expression of pros- 25 
tasin. Our data indicate that prostasin is implicated in normal 
prostate biology and its down-regulation in prostate cancer, 
and its absence in invasive prostate and breast cancer cell 
lines indicates increased invasiveness. Our results also indi-
cate that delivering a functional human prostasin gene to 30 
invasive prostate and breast cancers can reduce the inva-
s1veness. 
For a facile understanding of the invention embodied 
herein, reference should now be made to FIGS. 1and2. FIG. 
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blot analysis (upper panel), prostasin (as a 40-kDa band) was 
detected in normal human prostate epithelial cells (CC-
2555) and the LNCaP cells, but not in the DU-145 or PC-3 
cells. An equal amount of total protein (100 µg) was loaded 
for each sample. At the mRNA level, human prostasin 
mRNA (via a 232-bp amplified DNA band) was detected in 
normal prostate epithelial cells (CC-2555) and the LNCaP 
cells, but not in the DU145 or PC-3 cells as analyzed by 
RT-PCR/Southern blot hybridization (middle panel). 
Co-amplification of a 556-bp human ~-actin message (as 
shown in the gel photograph in the lower panel) confirmed 
the quality and the quantity of the RNA applied in each 
RT-PCR. 
Expression of prostasin protein is reduced in high-grade 
human prostate tumor. Prostatectomy specimens from 39 
patients (128 sections) were subjected to immunohistochem-
istry using a prostasin-specific antibody. Overall, in non-
tumor or benign prostate epithelia, 89.0% of the examined 
areas demonstrated positive staining for prostasin protein 
and 11.0% were considered negative (based on the scoring 
system used for HercepTest™, DAKO Corporation, 
Carpinteria, Calif.). In all tumor specimens that were 
examined, prostasin was detected in 93.3% of the low 
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3 
areas, 21.1 % of Gleason grade 4 areas, but not in Gleason 
grade 5 areas (data summarized in Table 1). The mean 
prostasin immunostaining score was found significantly 
decreased in high-grade prostate tumors as compared to 
non-tumor areas (ANOVA, p<0.0001). 
Representative staining images of non-tumor (benign) 
areas and prostate tumor areas are shown in FIGS. 4a-4l, 
which provides immunohistochemical detection of prostasin 
protein in tissues. Paraffin-embedded human prostate sec-
tions were stained for prostasin protein expression evalua-
tion using a specific antibody as described (Yu J X. Chao L. 
Chao J. Prostasin is a novel human serine proteinase from 
seminal fluid. Purification, tissue distribution, and localiza-
tion in prostate gland. Journal of Biological Chemistry. 
269(29):18843-8, 1994). Prostasin positive staining (brown 
1 sets forth a schematic for determining if a male has 35 
prostate cancer. Human blood 10 is taken from the male and 
analyzed for the presence of prostasin serine protease 14. If 
NO 12 prostasin is found, there is probably little or no 
cancer. If there is a presence YES 16 of prostasin serine 
protease 14, there is prostate cancer. 40 color) was detected in the cytoplasm and apical membrane 
in non-tumor or benign epithelial cells. If a biopsy of the prostate gland 20 is analyzed for the 
presence of a normal amount YES 22 of prostasin serine 
protease 14, there is no cancer or there is non-invasive 
cancer. If there is NO 24 or Reduced 26 amount of prostasin 
The prostasin protein was detected in the cytoplasm and 
serine protease 14, there is invasive cancer. 45 
on the plasma membrane (apical) of benign epithelial cells 
lining the secretory lumen as well as in the secretion inside 
the lumen (FIGS. 4A and 4B, score 3, or+++), confirming 
the results of (Yu J X. Chao L. Chao J. Prostasin is a novel 
FIG. 2 sets forth a schematic for determining if a female 
has breast cancer. Human blood 100 is taken from the female 
and analyzed for the presence of prostasin serine protease 
140. If NO 120 prostasin is found, there is prospectively no 50 
cancer. If there is a presence YES 160 of prostasin serine 
human serine proteinase from seminal fluid. Purification, 
tissue distribution, and localization in prostate gland. Journal 
of Biological Chemistry. 269(29):18843-8, 1994). When a 
pre-immune rabbit serum was used in place of the prostasin 
antiserum, no staining was observed in either the non-tumor 
protease 140, there is breast cancer. If a biopsy of the breast 
200 is analyzed for the presence of YES 220 of prostasin 
serine protease 140, there is no invasive cancer but may be 
non-invasive cancer. If there is NO 240 or Reduced 260 
55 
amount of prostasin serine protease 140, there is invasive 
epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E). 
Tumor epithelia displayed various degrees of prostasin 
immunostaining as shown in FIGS. 4F-4L. In Gleason grade 
1-2 tumors, moderate prostasin staining is seen in the 
cytoplasm and on the plasma membrane of some epithelial 
cancer. 
The levels of prostasin protein in the epithelial cells of the 
human prostate gland can be used as a diagnostic marker for 
the potential invasiveness of prostate tumors. The support-
ing evidence came from our findings that two invasive 
human prostate cancer cell lines DU-145 and PC-3 do not 
express prostasin while normal prostate epithelial cells and 
a non-invasive prostate cancer cell line LNCaP express both 
the prostasin mRNA and protein 
Refer now to FIG. 3 which shows human prostasin 
expression in prostate epithelial cells. By means of western 
cells, as well as in the secretion in the lumen (FIGS. 4G and 
4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser 
number of epithelial cells displayed the moderate level 
60 prostasin staining (FIGS. 4I and 41). In Gleason grade 4 
tumors, most epithelial cells did not show any prostasin 
staining, while some prostasin staining can be seen in rare, 
sporadic tumor cells (FIGS. 4K and 4L, as indicated by the 
arrow, score 0). Genetically, prostate tumors are heteroge-
65 neons and multi-focal in nature, in that one patient's gross-
anatomy tumor comes from multiple initial lesions which 
are caused by different initial transformation events and 
US 6,569,684 B2 
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progress to different stages by different ensuing transforma-
tions (Isaacs J T. Bova GS. Prostate Cancer. In The Genetic 
Basis of Human Cancer (Eds. Vogelstein B and Kinzler K 
W), pp653-60, McGraw-Hill Health Professions Division, 
1998). The Gleason grading, when used as a percentage of 5 
each cancer occupied by Gleason grade 4/5 areas, is inde-
pendently associated with prostate cancer progression 
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M, 
Johnstone I M. Biological determinants of cancer progres-
sion in men with prostate cancer. JAMA 281:1395-1400, 10 
1999). We found a significant decrease of prostasin expres-
sion in the high-grade, i.e., the more progressively trans-
formed tumors. 
As earlier indicated, FIG. 5 shows human prostasin 
expression in human breast cancer cell lines. By means of 15 
western blot analysis (upper panel), prostasin (as a 40-kDa 
band) was detected in MCF-7 cells, but not in MDA-MB-
453, MDA-MB-231, or MDA-MB-435s cells. An equal 
amount of total protein (100 µg) was loaded for each sample. 
At the mRNA level, human prostasin mRNA (via a 232-bp 20 
amplified DNA band) was detected in MCF-7 and MDA-
MB-453 cells, but not in the MDA-MB-231 or MDA-MB-
435s cells as analyzed by RT-PCR/Southern blot hybridiza-
tion (lower panel). 
Prostasin mRNAexpression is seen absent in two invasive 25 
human breast cancer cell lines while two non-invasive breast 
cancer cell lines express prostasin mRNA or protein. Analy-
14 
fragments are generated in the methylation-sensitive 
digestion, suggesting incomplete methylation (one of two or 
more chromosomes) or clonal methylation in a sub-
population of cells. For the MDA-MB-231 and MDA-MB-
435, however, the Hpa II digestion did not yield the 1,052 bp 
but rather gave the 1,275-bp fragment. This homogeneous 
methylation pattern indicates that the Msp I/Hpa II site, at 
location-95 (relative to the transcription initiation site) of the 
prostasin promoter, is methylated (hypermethylated) in 
these DNA samples. Signal intensity variation may be 
attributed to aneuploidy. 
An examination of the prostasin gene promoter region for 
DNA methylation differences among human prostate and 
breast cancer cell lines has been made.(see FIG. 6). We 
found that cells that express prostasin, normal prostate 
epithelial, LNCaP, and MCF-7, are unmethylated in the 
prostasin promoter while MDA-MB-453 showed heteroge-
neous prostasin promoter methylation. For cells that do not 
express prostasin, DU-145 and PC-3 showed heterogeneous 
prostasin promoter methylation while MDA-MB-231 and 
MDA-MB-435 showed homogeneous hypermethylation in 
the promoter region of the prostasin gene. 
Two human prostate cancer cell lines that do not express 
prostasin, the highly invasive DU-145 and PC-3, show 
heterogeneous methylation in the promoter region of the 
prostasin gene. The result suggests that at least one of the 
two (or more) chromosome 16's of these cell lines is 
methylated at the prostasin gene locus. The prostasin gene 
on the unmethylated chromosome may contain mutations 
that silenced the expression. An alternative explanation for 
the heterogeneous methylation pattern is that the methyla-
tion occurs in clonal cell populations, however, the lack of 
detectable prostasin mRNA in our RT-PCR-Southern blot 
analysis in the DU-145 and PC-3 cells argues against this 
possibility. 
sis of prostasin expression in human breast cancer cell lines 
showed that the non-invasive MCF-7 and MDA-MB-453 
cells express the prostasin mRNA while the highly invasive 30 
MDA-MB-231 and MDA-MB-435s cells do not express the 
prostasin mRNA (see FIG. 5). Expression of prostasin 
mRNA in normal human breast can be demonstrated by the 
presence of two GenBank™ normal human breast EST 
sequences coding for prostasin (Accession numbers 35 
R48653, and R48557). The MCF-7 cells also express the 
prostasin protein as determined by western blot analysis 
(again see FIG. 5). 
The significance of the finding on prostasin gene promoter 
hypermethylation in prostate or breast cancer is that the 
measurement of prostasin down-regulation as a cancer 
40 
marker may be achieved by using a binary assay (yes-or-no), 
instead of a gradually decreasing quantity in the immuno-
histochemistry assay (which is quite arbitrary). 
Prostasin down-regulation in prostate or breast cancer can 
be caused by promoter methylation or gene-specific muta-
tion. Prostasin expression decreases with increasing prostate 
cancer grade and is absent in invasive prostate and breast 
cancer cell lines. The chromosomal locus where the human 
prostasin gene is, 16pll.2, however, is not known to be an 
LOH hot-spot in prostate cancer or in breast cancer. Epige- 45 
netic events (such as DNA methylation) may be an alterna-
tive mechanism of loss of expression for tumor suppressors 
or invasion suppressors. Refer now to FIG. 6 which shows 
promoter hypermethylation of the human prostasin gene in 
human prostate and breast cancer cell lines. Genomic DNA 50 
( 5 µg) from the various cell lines (as indicated in the figure) 
were digested with the following restriction enzyme 
combinations, Xho I/BamH I(X/B, flanking cuts of the 
methylation-sensitive site), Xho I/BamH I/Msp I (X/B/M), 
or Xho l/BamH l/Hpa II (X/B/H). The digests were resolved 55 
in a 0.8% agarose gel and transferred to an Immobilon-N 
membrane for hybridization with a nick-translated prostasin 
promoter probe (bases 703-1469 of the prostasin gene 
sequence U33446). The probe detects a promoter fragment 
of 1,275 bp, which is cut by the methylation-insensitive 60 
enzyme Msp I to yield a 1,052-bp fragment for all DNA 
samples. The methylation-sensitive isoschizomer Hpa II 
yields the 1,052-bp fragment in the CC-2555 (normal pros-
tate epithelial cells), the LNCaP, and the MCF-7 samples, 
indicating the hypomethylated or unmethylated state of the 65 
prostasin promoter in these cells. For DU-145, PC-3, and 
MDA-MB-453 DNA, both the 1,052-bp and the 1,275-bp 
Re-expression of human prostasin protein in invasive 
human prostate and breast cancer cells reduces invasiveness 
in vitro. At this point, reference should be made to FIG. 7 
which shows the prostasin protein expression and in vitro 
invasive properties of the DU-145 and the PC-3 transfec-
tants. DU-145 or PC-3 cells transfected with either a vector 
DNA (labeled as "vector") or a prostasin cDNA construct 
(labeled as "prostasin") were analyzed by a western blot 
analysis using a prostasin-specific antibody (upper panel) or 
subjected to an in vitro Matrigel chemoinvasion assay 
(lower panel) as described in (Liu D F. Rabbani S A 
Induction of urinary plasmiinogen activator by retina acid 
results in increased invasiveness of human prostate cancer 
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed 
human prostasin protein (a 40-kDa band) was detected in the 
prostasin cDNA-transfected DU-145 or PC-3 cells, but not 
in the vector-transfected cells. In the Matrigel chemoinva-
sion assay, the vector-transfected cells are expressed as 
being 100% invasive (solid bar), the open bar represents the 
relative invasiveness of the human prostasin cDNA-
transfected cells. The data were analyzed by a Student t-test 
using the Stat view software (Abacus Concepts, Inc., 
Berkeley, Calif.). 
It can be seen that Polygonal DU-145 and PC-3 cells 
transfected with the human prostasin cDNA (designated 
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DU-145/Pro, and PC-3/Pro, respectively) were confirmed to 
express the human prostasin protein, as shown in the western 
blot analysis of the cell lysate (FIG. 7, upper panel). The 
vector-transfected cells, designated DU-145/Vector or PC-3/ 
Vector, respectively, were used as negative control in the 
western blot. A further examination of the DU-145/Pro and 
the PC-3/Pro cells by immunocytochemistry confirmed that 
100% of the cells expressed the prostasin protein (data not 
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7, 
lower panel), the invasiveness of DU-145/Pro cells was 
determined to be at 32% of that of DU-145Nector cells (or, 
the reduction of invasiveness was at 68%). The invasiveness 
of PC-3/Pro cells was determined to be at 58% of that of 
PC-3Nector cells (or, the reduction of invasiveness was at 
42%). We performed in vitro cell proliferation assays on 
DU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs. 
PC-3/Vector cells, but did not observe any difference 
between the growth rates of the prostasin cDNA-transfected 
or the vector-transfected cells over an 8-day period (data not 
shown). 
Forced re-expression of human prostasin in two invasive 
human breast cancer cell lines reduced invasiveness. A 
full-length human prostasin cDNA under the control of an 
RSV promoter was transfected into the invasive breast 
cancer MDA-MB-231 and MDA-MB-435 cells. Reference 
should be made to FIG. 8 which shows prostasin protein 
expression and in vitro invasive properties of the MDA-
MB-231 and the MDA-MB-435s transfectants. MDA-MB-
231 and MDA-MB-435s cells transfected with either a 
vector DNA (labeled as "vector") or a prostasin cDNA 
construct (labeled as "prostasin") were analyzed by a west-
ern blot analysis using a prostasin-specific antibody (upper 
panel) or subjected to an in vitro Matrigel chemoinvasion 
assay (lower panel) as referenced in (Liu D F. Rabbani S A 
Induction of urinary plasminogen activator by retina acid 
results in increased invasiveness of human prostate cancer 
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed 
human prostasin protein (a 40-kDa band) was detected in the 
prostasin cDNA-transfected MDA-MB-231 and MDA-MB-
435s cells, but not in the vector-transfected cells. In the 
Matrigel chemoinvasion assay, the vector-transfected cells 
are expressed as being 100% invasive (solid bar), the open 
bar represents the relative invasiveness of the human pros-
tasin cDNA-transfected cells. The data were analyzed by a 
Student t-test using the Stat view software (Abacus 
Concepts, Inc., Berkeley, Calif.). 
Stable, polyclonal, episomal transfectants were obtained 
and the expression of human prostasin protein was con-
firmed by western blot analysis (FIG. 8, upper panel). In in 
vitro Matrigel chemoinvasion assays, the invasiveness of 
either cell lines expressing human prostasin was reduced by 
50% as compared to the vector-transfected controls (FIG. 8, 
lower panel). 
Taken together, the foregoing evidences linking prostasin 
level reduction or protasin absence to the invasiveness of 
prostate and breast cancer cell lines, or linking prostasin 
expression to reduced invasiveness. The evidence qualifies 
prostasin as an invasion suppressor, which thus is a marker 
for diagnosis of invasiveness of prostate and breast cancers, 
or as a therapeutic agent to treat invasive prostate and breast 
cancers. 
Pathological grading by the Gleason system is performed 
after either surgery or biopsy, both highly invasive 
procedures, while blood tests such as that for the PSA 
prostate cancer marker can offer the hope of accurate diag-
nosis and prognosis without the harm of an invasive proce-
dure. In practice, however, single markers suffer from an 
16 
intrinsic limitation that the "positive" identifications are not 
always confirmed for the "diagnosed" disease. Biopsy is still 
required for a true positive identification of prostate cancer 
even in the case of the application of the PSA prostate cancer 
5 marker (Catalana W J. Partin AW. Slawin KM. Brawer M 
K. Flanigan R C. Patel A Richie J P. deKernion J B. Walsh 
P C. Scardino P T. Lange P H. Subong E N. Parson R E. 
Gasior G H. Loveland K G. Southwick P C. Use of the 
percentage of free prostate-specific antigen to enhance dif-
10 ferentiation of prostate cancer from benign prostatic disease: 
a prospective multicenter clinical trial [see comments]. 
JAMA 279(19):1542-7, 1998). As stated above, it has been 
demonstrated in principle that many markers used in a 
multivariate approach may provide a highly accurate diag-
15 nosis (Greene G F. Kitadai Y. Pettaway CA von Eschenbach 
A C. Bucana C D. Fidler I J. Correlation of metastasis-
related gene expression with metastatic potential in human 
prostate carcinoma cells implanted in nude mice using an in 
situ messenger RNA hybridization technique. American 
20 Journal of Pathology. 150(5):1571-82, 1997). From the 
standpoint of prostate cancer genetics, the multivariate 
approach is well supported by our current understanding. A 
serine protease structurally and genetically related to the 
PSA, the hK2 (human glandular kallikrein 2) has shown 
25 some promise of joining the list of markers applicable for 
prostate cancer diagnosis (Saedi M S. Hill T M. Kuus-
Reichel K. Kumar A Payne J. Mikolajczyk SD. Wolfert R 
L. Rittenhouse H G. The precursor form of the human 
kallikrein 2, a kallikrein homologous to prostate-specific 
30 antigen, is present in human sera and is increased in prostate 
cancer and benign prostatic hyperplasia. Clinical Chemistry. 
44(10):2115-9, 1998). Structurally and in prostate gland 
biology, prostasin shares many common characteristics with 
both PSA and hK2, as being a secreted serine protease made 
35 in large abundance in prostate epithelial cells (Yu J X. Chao 
L. Chao J. Prostasin is a novel human serine proteinase from 
seminal fluid. Purification, tissue distribution, and localiza-
tion in prostate gland. Journal of Biological Chemistry. 
269(29):18843-8, 1994; Yu J X. Chao L. Chao J. Molecular 
40 cloning, tissue-specific expression, and cellular localization 
of human prostasin mRNA Journal of Biological Chemistry. 
270(22):13483-9, 1995). While high-grade prostate cancer 
cells produce less PSA protein than normal prostate cells or 
low-grade prostate cancer cells (Hakalahti L. Vihko P. 
45 Henttu P. Autio-Harmainen H. Saini Y. Vihko R. Evaluation 
of PAP and PSAgene expression in prostatic hyperplasia and 
prostatic carcinoma using northern-blot analyses, in situ 
hybridization and immunohistochemical stainings with 
monoclonal and bispecific antibodies. International Journal 
50 of Cancer. 55(4):590-7, 1; Sakai H. Yogi Y. Minami Y. 
Yushita Y. Kanetake H. Saito Y. Prostate specific antigen and 
prostatic acid phosphatase immunoreactivity as prognostic; 
Sakai H. Yogi Y. Minami Y. Yushita Y. Kanetake H. Saito Y. 
Prostate specific antigen and prostatic acid phosphatase 
55 immunoreactivity as prognostic), the serum PSA levels in 
prostate cancer patients increase due to tissue damage 
caused by invasive cancer (Rittenhouse H G. Finlay J A 
Mikolajczyk SD. Partin AW. Human Kallikrein 2 (hK2) and 
prostate-specific antigen (PSA): two closely related, but 
60 distinct, kallikreins in the prostate. [Review] [ 457 refs] 
Critical Reviews in Clinical Laboratory Sciences. 35( 4): 
275-368, 1998). By comparison, we also believe prostasin 
is in the circulation of prostate cancer patients. As a result, 
a blood test for the circulating prostasin to indicate the 
65 presence and/or the stage of prostate cancer would be highly 
useful. (as illustrated in FIG. 1). In principal, the feasibility 
of a blood test based on prostasin detection to indicate 
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While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
cancer has been demonstrated by Berteau et al. (1999). 
These authors (Berteau P. Laribi Eschwege P. Lebars I. 
Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect 
prostate cells in blood of cancer patients. Clinical and 
Chemical Laboratory Medicine 37 (SS): S119, 1999), dem-
onstrated a highly promising potential of using prostasin as 
a marker to detect circulating prostate epithelial cells, a sign 
5 deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. of prostate tissue damage caused by invasive prostate cancer 
leading to the dissemination of prostate epithelial cells into 
the circulation. It is expected that a blood test for circulating 10 
prostasin to indicate the presence and/or the stage of breast 
cancer would be highly useful. (as illustrated in FIG. 2). 
In summary of the invention, it has been taught herein 
that: protein prostasin as well as its MRA levels and its gene 
promoter DNA methylation levels can be used to determine 15 
the invasiveness level of human carcinomas; and, provide a 
method of treating invasive human carcinomas by delivery 
thereto of a recombinant nucleic acid formed by a human 
prostasin nucleic acid incorporated into a selected gene 
delivery vector. Those teachings are repeated for emphasis 20 
in the following: 
1. Immunohistochemistry studies of human prostate can-
cer specimens revealed a down-regulation of prostasin 
in high-grade tumors. 
2. Using RT-PCR and western blot analyses, prostasin 
25 
protein and mRNA expression were found in a non-
invasive human breast cancer cell line, MCF-7, while 
invasive human breast cancer cell lines MDA-MB-231 
and MDA-MB-435s were found not to express either 
30 
the prostasin protein or the mRNA. A non-invasive 
human breast cancer cell line, MDA-MB-453, was 
shown to express prostasin mRNA but not prostasin 
protein: and, 
3. Examination of the prostasin gene promoter in the 35 
human prostate and breast cancer cell lines by Southern 
blot analysis revealed heterogeneous methylation of the 
promoter in DU-145, PC-3 and MDA-MB-453 cells, 
and homogeneous methylation of the promoter in 
MDA-MB-231 and MDA-MB-435s cells. The prosta- 40 
sin gene promoter in normal human prostate epithelial 
cells, the LNCaP and the MCF-7 cells was shown to be 
unmethylated. Transfection of DU-145 and PC-3 cells 
with a full-length human prostasin cDNA restored 
prostasin expression and reduced the in vitro invasive- 45 
ness by 68% and 42%, respectively. Transfection of 
MDA-MB-231 and MDA-MB-435s cells with a full-
length human prostasin cDNA restored prostasin 
expression and reduced the in vitro invasiveness by 
50% for either cell line. 50 
The preferred methods of separating sampled human 
carcinoma tissue from neighboring normal tissues is by laser 
capture micro-dissection. 
We claim: 
1. A method of determining human prostate carcinomas 
non-invasiveness using prostasin gene promoter DNA 
methylation levels, comprising the steps of: 
sampling a human prostate carcinoma tissue; 
determining prostasin gene promoter DNA methylation 
levels in the human carcinoma tissue; and 
determining the human prostate cancer is not invasive 
based on the lack of DNA methylation of the prostasin 
gene promoter. 
2. The method of claim 1, wherein the step of determining 
gene promoter DNA methylation levels includes: 
applying prostasin-promoter-specific DNA probes in a 
southern blot hybridization analysis to determine the 
prostasin gene promoter DNAmethylation levels in the 
sampled human prostate carcinoma tissue. 
3. The method of claim 1, wherein the sampling com-
prises: 
separating the human carcinoma tissue from the neigh-
boring normal tissue by laser capture micro-dissection. 
4. A method of determining human breast carcinomas 
non-invasiveness using prostasin gene promoter DNA 
methylation levels, comprising the steps of: 
sampling a human breast tissue; 
determining prostasin gene promoter DNA methylation 
levels in the human carcinoma tissue; and 
determining the human prostate cancer is not invasive 
based on the lack of DNA methylation of the prostasin 
gene promoter. 
5. The method of claim 4, wherein the step of determining 
gene promoter DNA methylation levels includes: 
applying prostasin-promoter-specific DNA probes in a 
southern blot hybridization analysis to determine the 
prostasin gene promoter DNAmethylation levels in the 
sampled human breast carcinoma tissue. 
6. The method of claim 4, wherein the sampling com-
prises: 
separating the human carcinoma tissue from the neigh-
boring normal tissue by laser capture micro-dissection. 
* * * * * 
